| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4703
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-435
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 |
| filingDate |
2004-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2007-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2007528710-A |
| titleOfInvention |
Endogenous peptides and active subfragments thereof |
| abstract |
The present invention relates to a substantially pure and biologically active continuous anti-angiogenic polypeptide comprising the central region of human histidine-rich glycoprotein (HRGP). This polypeptide is shown to contain potential endogenous natural subfragments of human HRGP that contain anti-angiogenic activity similar to the mature protein. The invention also relates to one or more new subfragments of human HRGP that are biologically active from such a central region. All such subfragments are characterized by having anti-angiogenic activity. One of the active subfragments is called Pep2. Also included within the scope of the invention are anti-angiogenic subfragments derived from Pep2, one of which contains the newly identified minimally functional entity at present. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013183494-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020003978-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9696321-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019230509-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9504731-B2 |
| priorityDate |
2003-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |